Tim Pardee, MD, PhD

Professor, Hematology and Oncology

Research Interests

Leukemia, Myeloid, Acute
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Myelodysplastic Syndromes
Leukemia, Myelogenous, Chronic, BCR-ABL Positive

About Me

Research Laboratory

Tim Pardee Lab - Focused on developing a better understanding of Acute Myeloid Leukemia (AML)

Educational Program Involvement

Cancer Biology PhD
Program Research Interest: Cellular defense and metabolism, Aberrant signaling pathways in tumor cells, Cell growth and survival, Molecular cancer epidemiology, Gene-environment interactions, Cancer control

Integrative Physiology and Pharmacology PhD
Program Research Interest: Drug and Alcohol Abuse, Cardiovascular Physiology and Hypertension, Regenerative Medicine, Neuro- and Behavioral Pharmacology, Cancer Therapeutics Endocrinology, Diabetes, and Metabolism Lifespan Physiology.

Molecular Genetics and Genomics PhD
Program Research Interest: Identification of genetic variants that contribute to complex disease, Gene-environment interactions, Epigenetics, Genetic epidemiology, Bioinformatics

Education: MD, University at Buffalo State University of New York School of Medicine, 2003
Residency: Internal Medicine, Massachusetts General Hospital, 2005
Fellowship: Hematology / Oncology, University Hospital State University of New York Health Science Center Stony Brook, 2009
Board Certifications: American Board of Internal Medicine, Hematology; American Board of Internal Medicine, Medical Oncology
Positions: Professor, Hematology and Oncology; Professor, Cancer Biology; Professor, Wake Forest Institute for Regenerative Medicine
Departments and Affiliations: Hematology and Oncology; Cancer Biology; Wake Forest Institute for Regenerative Medicine; Comprehensive Cancer Center; Center for Redox Biology and Medicine

Efficacy of 10-day decitabine in acute myeloid leukemia. Bouligny IM, Mehta V, Isom S, Ellis LR, Bhave RR, Howard DS, Lyerly S, Manuel M, Dralle S, Powell BL, Pardee TS. Leuk Res. 2021 Apr; 103:106524.
A Pilot Phase II Study of the Feasibility and Efficacy of Vincristine Sulfate Liposome Injection in Patients With Relapsed or Refractory Acute Myeloid Leukemia. Seegars MB, Woods R, Ellis LR, Bhave RR, Howard DS, Manuel M, Dralle S, Lyerly S, Powell BL, Pardee TS. J Hematol. 2021 Feb; 10(1):1-7.
Geriatric assessment and survival among older adults receiving postremission therapy for acute myeloid leukemia. Saad M, Loh KP, Tooze JA, Pardee TS, Ellis LR, Powell BL, Bhave RR, Geiger AM, Williamson JD, Kritchevsky S, Klepin HD. Blood. 2020 12; 136(23):2715-2719.
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results. Heuser M, Palmisiano N, Mantzaris I, Mims A, DiNardo C, Silverman LR, Wang ES, Fiedler W, Baldus C, Schwind S, Pardee T, Perl AE, Cai C, Kaulfuss S, Lagkadinou E, Rentzsch C, Wagner M, Wilkinson G, Wu B, Jeffers M, Genvresse I, Krämer A. Leukemia. 2020 11; 34(11):2903-2913.
The Novel Phospholipid Mimetic KPC34 Is Highly Active Against Acute Myeloid Leukemia with Activated Protein Kinase C. Alexander PM, Kucera GL, Pladna KM, Pardee TS. Transl Oncol. 2020 Jul; 13(7):100780.

View More Publications

Study of DSP-5336 for Treatment of Leukemia

Research Interests

Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Energy Metabolism
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Precursor Cell Lymphoblastic Leukemia-Lymphoma

Technology Transfer and Commercialization

Research Focus Areas

Translation to Care

More Resources

Tim Pardee, MD, PhD

Research Interests

About Me

Research Laboratory

Educational Program Involvement